A no-deal Brexit could disrupt medicines supplies to the UK for at least six months because of delays as they are shipped across the channel, instead of the previously estimated six weeks, a government minister has warned. The website Hospital Pharmacy Europe reported that manufacturers may have to rethink logistics arrangements to avoid the delays when medicines are shipped via crossings at Dover and Folkestone. It cited a letter from MP Stephen Hammond, sent this month, written in response to ...
READ MORE
|
AMSBIO has introduced a range of purified cancer exosome samples to help researchers study the role of exosomes in cancer development and metastasis.By targeted filtration of patient serum using a specific binding method removes protein contaminant to isolate exosome at 95% high purity....
READ MORE
|
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing types....
READ MORE
|
Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech IFM Therapeutics, which was bought by Bristol-Myers Squibb in 2017 in a deal worth $2.3 billion. At the time IFM’s non-oncology assets were spun out into two biotechs – IFM Tre and IFM Due, focusing on NLRP3 antagonists, and cGAS/STING antagonists respectively. The acquisition gives Nov...
PHARMAPHORUM
READ MORE
|
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of GW Pharmaceuticals’ cannabis-based medicine Epidyolex (cannabidiol) for routine treatment on the National Health Service (NHS) to treat seizures. Epidyolex is plant-derived medicine in the form of an oral solution, used as an adjunctive treatment for seizures caused by Lennox Gastaut syndrome (LGS) and Dravet syndrome in patients aged two years and above. The oral solution secured approval an...
READ MORE
|
The drug used to manage some of the most salient symptoms of Parkinson's disease is known to expose patients to more motor issues, as part of its side effects. Researchers suggest that ketamine could be used to neutralize those side effects. ketamine chemical formula Researchers are planning a phase I clinical trial to test the dyskinesia relieving effects of ketamine. Parkinson's disease, a motor system disorder, is characterized by tremor, limb stiffness, impaired balance, and slowness...
READ MORE
|